FocalTherics (NASDAQ:FOCL) Upgraded to “Strong-Buy” at Mizuho

Mizuho upgraded shares of FocalTherics (NASDAQ:FOCL) to a strong-buy rating in a report published on Friday,Zacks.com reports.

A number of other analysts have also recently commented on the company. Wall Street Zen cut FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of FocalTherics in a report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $9.00.

FocalTherics Trading Down 0.2%

FOCL opened at $5.43 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79. The firm has a market capitalization of $203.52 million, a price-to-earnings ratio of -6.70 and a beta of -0.04. FocalTherics has a 12-month low of $1.21 and a 12-month high of $5.64.

FocalTherics (NASDAQ:FOCL) last released its earnings results on Thursday, May 7th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). FocalTherics had a negative return on equity of 137.61% and a negative net margin of 41.47%.The business had revenue of $20.48 million during the quarter, compared to analysts’ expectations of $19.46 million. Research analysts forecast that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Insider Transactions at FocalTherics

In related news, Director Joshua Levine bought 10,000 shares of the business’s stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $4.22 per share, with a total value of $42,200.00. Following the transaction, the director owned 35,000 shares in the company, valued at approximately $147,700. This trade represents a 40.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 10.10% of the company’s stock.

Hedge Funds Weigh In On FocalTherics

A number of institutional investors and hedge funds have recently modified their holdings of FOCL. Rock Springs Capital Management LP increased its position in FocalTherics by 7.1% during the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after acquiring an additional 91,500 shares during the last quarter. Lido Advisors LLC purchased a new position in FocalTherics in the first quarter worth about $40,000. SmartHarvest Portfolios LLC bought a new stake in shares of FocalTherics during the 1st quarter valued at about $38,000. Flax Pond Capital LLC bought a new stake in shares of FocalTherics during the 4th quarter valued at about $2,623,000. Finally, Kovack Advisors Inc. purchased a new stake in shares of FocalTherics during the 4th quarter valued at about $53,000. 62.74% of the stock is currently owned by hedge funds and other institutional investors.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.